Instalab
logoInstalab

Blastocystis Hominis

Stool Test
Find out if a common gut parasite is driving your unexplained digestive issues, hives, or chronic bloating.
4.9 (2,802 reviews)
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Self-collect at home
Easy self-collection kit
Get results
Explained with clear next steps, no medical jargon

Should you take a Blastocystis Hominis test?

This test is most useful if any of these apply to you.

Living With Unexplained Digestive Issues
If chronic bloating, loose stools, or abdominal pain has not been explained by standard testing, this can find a parasite that routine panels miss.
Battling Chronic Hives or Itching
If you have unexplained urticaria or itching that has not responded to allergy treatment, this checks for a known parasitic trigger.
Already Managing IBS or IBD
If you have irritable bowel syndrome or inflammatory bowel disease, this can identify a gut parasite that is unusually common in your group.
Living With Weakened Immunity
If you have HIV, are on chemotherapy, or take immunosuppressive drugs, this checks for an opportunistic gut parasite that can cause serious illness.

About Blastocystis Hominis

If you have lingering bloating, loose stools, abdominal pain, or unexplained hives that no doctor has been able to pin down, a gut parasite called Blastocystis is one of the most overlooked possibilities. It shows up in human stool more often than almost any other intestinal organism, and standard stool tests miss it routinely.

Whether Blastocystis is causing your symptoms is genuinely complicated. It often lives in healthy people without causing trouble, but in some people, particularly those with certain subtypes or weakened immunity, it can drive chronic gastrointestinal misery and skin problems that resolve once it is treated.

What This Test Actually Detects

Blastocystis hominis (often just called Blastocystis) is a single-celled organism, technically a protist, that lives in the large intestine. It is not a protein, hormone, or chemical you can measure on a blood panel. The test looks for the organism itself in your stool, either under a microscope, in culture, or by detecting its DNA with a polymerase chain reaction (PCR) test, a method that finds genetic material from the parasite.

There are at least 17 to 28 genetically distinct subtypes of Blastocystis, labeled ST1 through ST28. Subtypes 1 through 4 cause most human infections, with ST3 being the dominant subtype across most regions. The subtype matters because pathogenicity appears to vary: ST1, ST4, and ST7 are more often linked to symptoms and disease, while ST2 is more often found in healthy carriers.

You pick it up the way you would pick up most gut bugs: from contaminated water, food, soil, or environmental exposure. Blastocystis has been detected in animals, water sources, and produce in many regions, and shared subtypes between humans and animals point to possible animal-to-human transmission.

Why Many People Have It and Feel Fine

Up to half of infected people stay asymptomatic for months or even years. In a study of 2,800 immunocompetent adults, no correlation was found between the presence of Blastocystis and gastrointestinal symptoms. In a study from Iran of 345 people, Blastocystis was actually more common in healthy individuals than in those with digestive complaints.

The picture gets more interesting in larger datasets. A global metagenomic analysis of 56,989 people across 32 countries found that carrying Blastocystis was associated with healthier diets, lower body mass index (BMI, a measure of weight relative to height), better lipid profiles, and lower levels of GlycA, a blood marker of systemic inflammation. People colonized with Blastocystis often have more diverse gut bacteria, sometimes considered a marker of a healthier microbiome.

Reconciling the Mixed Evidence

These findings can feel contradictory: some research treats Blastocystis as a parasite to clear, while other research suggests its presence tracks with better health. Both can be true. Blastocystis is not a simple "good or bad" marker. Its impact depends on which subtype you carry, the state of your gut bacteria, your immune health, and whether you have other coinfections. A positive test in a healthy person with a balanced microbiome may mean little. The same positive test in someone with chronic diarrhea, weakened immunity, or unexplained urticaria carries very different weight.

Digestive Symptoms and IBS

When Blastocystis does cause symptoms, the most common are abdominal pain, loose stools or chronic diarrhea, bloating, flatulence, and constipation. Some people experience nausea or fatigue alongside gut complaints. In a series of patients with these symptoms treated with metronidazole, an antibiotic, many became asymptomatic and tested negative on follow-up.

Blastocystis is also detected at high rates in people with irritable bowel syndrome (IBS), with prevalence reaching up to 76% in some IBS cohorts. Detection in colonic aspirate samples taken during colonoscopy can find Blastocystis when standard stool tests miss it, and treating it has improved symptoms in selected IBS patients.

Skin Conditions and Hives

Chronic urticaria (hives) and unexplained itching or rash have been linked to Blastocystis in multiple studies. In one series of 104 urticaria patients, 61% tested positive for Blastocystis, and symptoms cleared after treatment with metronidazole.

If you have chronic hives or itching that has not responded to standard allergy treatment, checking for Blastocystis is a reasonable step that many dermatologists overlook.

Risk in Weakened Immunity

In people with HIV, cancer, or other significant immunosuppression, Blastocystis behaves more like a clear pathogen. In a multicenter study of 1,245 people living with HIV, viral load and CD4 cell counts (markers of how active the virus is and how strong the immune response is) were better predictors of Blastocystis infection than other factors. Case reports describe severe disease, including ascitic infection in a patient with rectal carcinoma and large colonic ulcers in a traveler, both of which improved with metronidazole.

Subtype and Pathogenicity

Not every Blastocystis carrier faces the same risk. Subtype identification, available with PCR-based testing, can help interpret what a positive result means.

SubtypeWhat It Tends to Mean
ST1More often linked to symptoms in humans and greater intestinal pathology in animal models
ST2Repeatedly found in asymptomatic carriers and considered likely non-pathogenic
ST3The most common subtype globally; often found in healthy people but sometimes linked to symptoms
ST4More associated with infectious diarrhea, particularly in Europe
ST7Linked to lower gut bacterial diversity and pathogenic behavior in diarrheal patients

Source: Popruk et al., 2021; Hussein et al., 2008; Deng et al., 2022; Bart et al., 2013.

What this means for you: a positive test that includes subtype information is more useful than presence/absence alone. If you test positive and have symptoms, knowing whether it is ST1, ST4, or ST7 (more concerning) versus ST2 (often benign) can help guide whether treatment is worth pursuing.

Reference Ranges

Blastocystis testing is qualitative: results are reported as detected or not detected, often with the subtype identified if PCR is used. There is no "normal range" or numerical cutoff. Some tests will report relative abundance, but no clinical guideline defines a level above which Blastocystis becomes pathogenic. Symptom severity does not consistently track with parasite quantity.

  • Not detected: the test did not find Blastocystis in your sample. This does not fully rule it out if microscopy was used, since standard microscopy misses many infections.
  • Detected, no subtype: Blastocystis is present, but you do not know whether the strain is more likely to be benign or pathogenic.
  • Detected with subtype: the most informative result, especially for guiding whether treatment is worth pursuing.

When Results Can Be Misleading

The single biggest reason for a misleading result is the testing method itself. Standard stool microscopy has low sensitivity for Blastocystis. Reviews show that PCR detects substantially more infections than microscopy or the routine ova-and-parasite exam. A negative result on a standard panel does not reliably exclude Blastocystis.

  • Microscopy alone: can miss infections that PCR would catch. If your symptoms persist and a basic stool exam was negative, ask for PCR-based testing.
  • No subtyping: without subtype information, you cannot tell whether your strain is the more benign ST2 or one of the more concerning subtypes.
  • Co-infections: Blastocystis often shows up alongside other parasites or gut pathogens. A positive result does not always mean Blastocystis is the actual cause of your symptoms.
  • Recent travel or antibiotics: travel to areas with high prevalence raises pretest probability, while recent antibiotic use can transiently reduce detectability.

Tracking Your Result Over Time

Blastocystis testing is not a marker you trend the way you would trend cholesterol or HbA1c, a measure of average blood sugar. The clinical question is binary at any given time: present or absent, with subtype if detected. The reason to retest is to confirm clearance after treatment or to recheck if symptoms return.

If you test positive and pursue treatment, retest 4 to 6 weeks after finishing the course to confirm clearance. If you test positive but stay asymptomatic and choose not to treat, there is no clear benefit to repeated retesting unless symptoms develop. If your initial test was microscopy-only and was negative but your symptoms persist, repeat with PCR rather than another microscopy exam.

What to Do With a Positive Result

A positive test alone is not a reason to start treatment. The decision depends on three things: whether you have symptoms, what subtype you carry, and whether other causes have been ruled out.

  • Positive and symptomatic: consider a broader gut workup that includes testing for other parasites, bacterial pathogens, and inflammatory markers like calprotectin (a stool marker of gut inflammation). A gastroenterologist can help interpret the full picture and decide on treatment.
  • Positive with weakened immunity: treatment is more clearly warranted, particularly if you have HIV, are on chemotherapy, or take immunosuppressive drugs. An infectious disease specialist is the right call.
  • Positive with chronic hives or skin issues: worth treating if standard allergy and dermatology workups have come up empty.
  • Positive and asymptomatic: treatment is rarely necessary. Large outcome data show little clinical benefit from clearing Blastocystis in healthy carriers.

The standard antiparasitic treatments studied in trials include metronidazole and nitazoxanide, both of which require a prescription. A randomized trial in 168 patients with persistent diarrhea found nitazoxanide cleared the organism in 86.6% of cases versus a much lower rate with placebo. Other trials, however, found no symptom improvement with metronidazole versus placebo, suggesting that not every positive case benefits from antibiotics.

What Moves This Biomarker

Evidence-backed interventions that affect your Blastocystis Hominis level

Decrease
Nitazoxanide course
Nitazoxanide, a prescription antiparasitic, can clear Blastocystis from your gut and resolve symptoms when it is the cause. In a trial of 168 children and adults with persistent diarrhea linked to Blastocystis, nitazoxanide produced 86.8% symptom resolution and 86.6% organism clearance on post-treatment stool tests, versus much lower rates with placebo. This is the most consistent eradication effect documented in randomized trials.
MedicationStrong Evidence
Increase
Exposure to contaminated water, food, soil, or animals
Blastocystis is acquired through the fecal-oral route, primarily from contaminated water, undercooked food, soil, or close contact with infected animals. Travel to regions with high prevalence increases your risk substantially: in a Dutch hospital series of 442 patients, travel to tropical countries was a clear risk factor for Blastocystis carriage. Multi-center French data from 788 people identified recent travel as a main risk factor. If you avoid these exposures, your odds of acquiring it drop.
LifestyleStrong Evidence
Decrease
Metronidazole course
Metronidazole is the most commonly prescribed antiparasitic for Blastocystis and can clear the organism in many cases, especially when it is the sole cause of diarrhea. A placebo-controlled trial reported clinical remission and parasitologic eradication in immunocompetent patients with Blastocystis-associated diarrhea, and case series report symptom resolution after a 7 to 10 day course. However, a separate randomized pilot trial of 50 patients with Blastocystis found no symptom improvement over placebo, and a pediatric trial of 40 children with recurrent abdominal pain found no advantage of trimethoprim-sulfamethoxazole over placebo. Treatment helps some people but not all.
MedicationModerate Evidence
Decrease
Saccharomyces boulardii (probiotic yeast)
Saccharomyces boulardii, a probiotic yeast, can reduce Blastocystis carriage and improve symptoms in children with Blastocystis-associated illness. In a randomized trial of 48 symptomatic children, S. boulardii showed beneficial effects comparable to metronidazole on symptoms and parasite clearance. This makes it a reasonable adjunct for people who prefer to avoid antibiotics or who have mild symptoms.
SupplementModerate Evidence
Increase
Plant-rich, healthier diet patterns
Healthier, more plant-rich diets are associated with higher Blastocystis prevalence in large datasets. In a global metagenomic analysis of 56,989 people, intestinal Blastocystis was linked to healthier diets, lower BMI, and more favorable cardiometabolic outcomes including higher HDL cholesterol and lower triglycerides. The presence of Blastocystis in this context is not a sign of disease and may even mark a healthier gut ecosystem, so a positive result on a healthy diet is rarely a reason for concern.
DietModerate Evidence

Frequently Asked Questions

References

55 studies
  1. Lepczyńska M, Białkowska J, Dzika E, Piskorz-ogórek K, Korycińska JEuropean Journal of Clinical Microbiology & Infectious Diseases2017
  2. Pawelec-pęciak O, ŁAnocha-arendarczyk N, Grzeszczak K, Kosik-bogacka DPathogens2025
  3. Popruk S, Adao D, Rivera WInfection, Genetics and Evolution2021
  4. Barbosa CV, Barreto MM, Andrade RJ, Sodré F, D'avila-levy CM, Peralta JM, Igreja R, De Macedo HW, Santos HLCPLoS ONE2018